Yujia Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yujia Chen has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Meniga Shengbu
State Key Laboratory of Southwestern Chinese Medicine Resources, School of Ethnic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China
1 shared publication - Qian Shi
State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China
1 shared publication Suolang Jiaqiu
State Key Laboratory of Southwestern Chinese Medicine Resources, School of Ethnic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China
1 shared publication- Xianrong Lai
State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China
1 shared publication Xinan Liu
State Key Laboratory of Southwestern Chinese Medicine Resources, School of Ethnic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China
1 shared publication
Latest Publications
- Open Access
- 21 February 2025
- Published by SAGE Publications in Natural Product Communications
- Vol. 20 (2)
Biomarkers: New Advances in Diabetic Nephropathy
Diabetic nephropathy (DN) is the leading cause of uremia and clinical mortality, characterized by the progressive deterioration of kidney structure and function due to prolonged exposure to hyperglycemia. This condition often necessitates renal replacement therapy for patients with end-stage-renal-disease (ESRD). Consequently, early detection, diagnosis, and treatment of DN are crucial to mitigate disease progression, enhance patient outcomes, and maintain a good quality of life. Exploring relevant biomarkers for the early diagnosis of DN holds significant importance. In recent years, numerous researchers have identified various novel biomarkers associated with diabetic nephropathy, which are critical for predicting both the onset and progression of the disease. This article aims to provide a comprehensive overview of the biomarkers related to DN.
- 21 February 2025
- Published by SAGE Publications in Natural Product Communications
- Vol. 20 (2)
Open AccessBiomarkers: New Advances in Diabetic Nephropathy
Diabetic nephropathy (DN) is the leading cause of uremia and clinical mortality, characterized by the progressive deterioration of kidney structure and function due to prolonged exposure to hyperglycemia. This condition often necessitates renal replacement therapy for patients with end-stage-renal-disease (ESRD). Consequently, early detection, diagnosis, and treatment of DN are crucial to mitigate disease progression, enhance patient outcomes, and maintain a good quality of life. Exploring relevant biomarkers for the early diagnosis of DN holds significant importance. In recent years, numerous researchers have identified various novel biomarkers associated with diabetic nephropathy, which are critical for predicting both the onset and progression of the disease. This article aims to provide a comprehensive overview of the biomarkers related to DN.